What is entailed in the recently announced GBM pre
Post# of 151351

(I'll show my way out thank you...)
From the March letter:
Quote:
The Company also continues to explore the possible use of leronlimab in the treatment of glioblastoma multiforme (“GBM”). A preclinical study at the Albert Einstein College of Medicine sequencing temozolomide and leronlimab is now underway. CytoDyn is also in discussions with several KOLs in neuro-oncology about the possibility of initiating a pilot study in patients with GBM, also based on currently available data.
Could this preclinical trial be based on the work alluded to in the Dec. letter by Dr. Pestell or is it that study?

